Medical Condition News

RSS

Watson commences shipment of generic Exelon

Watson Pharmaceuticals, Inc. announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is used to treat dementia in people with Alzheimer's disease.

1 Jul 2010

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.

1 Jul 2010

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

1 Jul 2010

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg strengths in the U.S. under the Prasco label.

1 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

Studies of a more-rapid-acting injectable human insulin formulation (VIAject®) in the treatment of type 1 and type 2 diabetes and of a novel insulin analog formulation (Vialog™) in an animal model of diabetes were reported this week in three poster presentations at the 70th Scientific Sessions of the American Diabetes Association in Orlando, Florida. The findings are based upon results from recent clinical and preclinical studies sponsored by Biodel Inc..

1 Jul 2010

AAO-HNS releases CCS to address ambiguities, disparities in diagnosis and management of nasal valve compromise

Today, the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) announced the release of a consensus statement to address ambiguities and disparities in the diagnosis and management of nasal valve compromise (NVC).

1 Jul 2010

Research findings suggest new treatment approach to improve corneal transplants

Although it is already one of medicine's most successful transplant procedures, doctors continue to seek ways to improve corneal transplants. Now, for the first time, a team of German and British researchers have confirmed that failure and rejection of transplanted corneas are more likely in patients whose eyes exhibit abnormal vessel growth, called corneal neovascularization, prior to surgery.

1 Jul 2010

Article that unveils exciting genetic research on alopecia areata published in Nature

On July 1, 2010, Nature Journal, the weekly, international, interdisciplinary journal of science, published an article that unveils the most exciting genetic research on alopecia areata to date. Led by the National Alopecia Areata Foundation Scientific Advisory Council member Dr. Angela Christiano, and using cases from the National Alopecia Areata Registry, a team of investigators from Columbia University Medical Center have found eight genes that contribute to alopecia areata, one of which has a possible role in the onset of the disease.

1 Jul 2010

Oxycyte PFCE decreases mortality after onset of decompression sickness in porcine model study

Oxygen Biotherapeutics, Inc. today announced that results from U.S. Navy studies demonstrated decreased mortality in porcine animal models that were given an intravenous dose of Oxycyte® perfluorocarbon emulsion (PFCE) after the onset of decompression sickness (DCS). These results showed a statistically significant decrease in mortality compared with the control group that did not receive Oxycyte PFCE. This data was published in the June issue of Aviation Space and Environmental Medicine.

1 Jul 2010

Majority of respondents receiving CAM therapy for back pain report great benefit: Study

A recent study, "Perceived Benefit of Complementary and Alternative Medicine for Back Pain" (Journal of the American Board of Family Medicine, May - June 2010, Vol. 23 No.3), found the majority of respondents receiving CAM for back pain reported great benefit from the various treatments.

1 Jul 2010

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

Preliminary results of a pre-specified subgroup study analysis of patients with diabetes and hypertension demonstrated that the investigational triple combination therapy of olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) resulted in a statistically significant greater Least Squares mean reduction in blood pressure from baseline at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as compared to corresponding dual combination therapy [olmesartan medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40 mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and hydrochlorothiazide (25 mg)].

1 Jul 2010

USPTO grants Semafore method patent for PI3K inhibitors

Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.

1 Jul 2010

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

The Florida Biomedical Research Program has awarded $2 million in biomedical research grants to three scientists from the Florida campus of The Scripps Research Institute.

1 Jul 2010

U-M scientists discover 12 more regions on genome with DNA variants associated with type 2 diabetes

An international team co-led by scientists from the University of Michigan have discovered 12 more regions on the genome with DNA variants that are associated with increased risk of type 2 diabetes, bringing the number to 38.

1 Jul 2010

Researchers uncover potential drug treatment for noise-induced hearing loss

Researchers from the University of Auckland, New Zealand, have discovered that a potent new drug restores hearing after noise-induced hearing loss in rats. The landmark discovery found that injection of an agent called 'ADAC', activates adenosine receptors in cochlear tissues, resulting in recovery of hearing function. The finding paves the way for effective non-surgical therapies to restore hearing loss after noise-induced injury. Dr. Srdjan Vlajkovic and his team's work1 is published in a special edition of Springer's journal Purinergic Signalling, focusing on the inner ear.

1 Jul 2010

Mutations in Siglec-8 gene may play role in asthma: Research

A gene that encodes a protein responsible for determining whether certain immune cells live or die shows subtle differences in some people with asthma, a team led by Johns Hopkins researchers reports in the June European Journal of Human Genetics.

1 Jul 2010

Best Friends Bill of Rights outlines 12 rules to help caregivers enhance lives of patients with Alzheimer's disease

Caring for someone with Alzheimer's or dementia can be a daunting task, even for the most experienced of professionals working with seniors daily in assisted living and memory care. Now there is help and guidance from the experts at Best Friends Approach Virginia Bell and David Troxel. The Best Friends Bill of Rights outlines 12 rules that when adapted, can make a world of difference in the quality of daily life to the one suffering as well as those acting in the role of caregiver.

1 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Medical Condition News

Watson commences shipment of generic Exelon

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

AAO-HNS releases CCS to address ambiguities, disparities in diagnosis and management of nasal valve compromise

Research findings suggest new treatment approach to improve corneal transplants

Article that unveils exciting genetic research on alopecia areata published in Nature

Oxycyte PFCE decreases mortality after onset of decompression sickness in porcine model study

Majority of respondents receiving CAM therapy for back pain report great benefit: Study

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

USPTO grants Semafore method patent for PI3K inhibitors

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

U-M scientists discover 12 more regions on genome with DNA variants associated with type 2 diabetes

Researchers uncover potential drug treatment for noise-induced hearing loss

Mutations in Siglec-8 gene may play role in asthma: Research

Best Friends Bill of Rights outlines 12 rules to help caregivers enhance lives of patients with Alzheimer's disease

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News